Retromers in Alzheimer's disease by Siegenthaler, Barbara & Rajendran, Lawrence
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Retromers in Alzheimer’s disease
Siegenthaler, Barbara; Rajendran, Lawrence
Abstract: Amyloid-￿ peptide (A￿), the key pathogenic agent in Alzheimer’s disease (AD), is released after
sequential proteolytic cleavage of the transmembrane amyloid precursor protein (APP). ￿-Site APP-
cleaving enzyme 1 (BACE1) cleaves APP in early endosomes, and the cause of increased BACE cleavage
of APP in AD is not fully resolved yet. It has been proposed that perturbed intracellular trafficking of
APP, which leads to prolonged residence time in early endosomes, influences A￿ production and hence
the risk for AD. Retromers are a family of proteins that mediate the retrieval of transmembrane pro-
teins from the endosomes to the trans-Golgi network. Misregulation of retromers or retromer-associated
proteins influences endosomal localization of APP/BACE1. Here we review the role of retromers in the
amyloidogenic processing of APP and their pathogenic role in AD.
DOI: 10.1159/000335910
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-63011
Published Version
Originally published at:
Siegenthaler, Barbara; Rajendran, Lawrence (2012). Retromers in Alzheimer’s disease. Neurodegenera-
tive Diseases, 10(1-4):116-121. DOI: 10.1159/000335910
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Neurodegenerative Dis 2012;10:116–121 
 DOI: 10.1159/000335910 
 Retromers in Alzheimer’s Disease 
 Barbara M. Siegenthaler    Lawrence Rajendran 
 Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research, University of Zurich,
 Zurich , Switzerland 
 [1] . Two characteristic pathological changes are observed 
in AD patient brains: intracellular tangles and extracel-
lular plaques in the hippocampus, cerebral cortex and in 
other areas of essential function for cognitive abilities  [2] . 
Plaques, which are thought to be a cause of AD, consist of 
secreted, aggregated and accumulated   -amyloid pep-
tides (A  )  [3] . A  is a cleavage product that is released 
after proteolytic processing of a transmembrane protein 
called the amyloid precursor protein (APP). APP plays a 
central role in the pathogenesis of AD and, depending on 
its intracellular trafficking, it is processed either by   -
secretase to the nonamyloidogenic soluble fragment 
 sAPP  or by   -secretase to sAPP  and a C-terminal 
 fragment that is further processed to the amyloidogenic 
A   [2] .
 APP,   -site APP-cleaving enzyme 1 (BACE1) and the 
  -secretase complex are all integral membrane protein 
components and hence are subjected to the regulation by 
intracellular trafficking. Recent evidence points out to 
the role of endocytosis by which APP and BACE1 are in-
ternalized into early endosomes where A  production 
occurs  [4] . Proteins that modulate the endosomal resi-
dency time of these proteins thus could modulate the pro-
duction of A  and hence have implications for AD. One 
group of such proteins are retromers that mediate the re-
trieval of transmembrane proteins from endosomes to 
the trans-Golgi network (TGN)  [5] . Retromers are het-
eropentameric proteins which bind to the cytosolic side 
of endosomes and mediate the retrograde transport of 
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 Abstract 
 Amyloid-  peptide (A  ), the key pathogenic agent in Alz-
heimer’s disease (AD), is released after sequential proteolyt-
ic cleavage of the transmembrane amyloid precursor protein 
(APP).   -Site APP-cleaving enzyme 1 (BACE1) cleaves APP in 
early endosomes, and the cause of increased BACE cleavage 
of APP in AD is not fully resolved yet. It has been proposed 
that perturbed intracellular trafficking of APP, which leads to 
prolonged residence time in early endosomes, influences A  
production and hence the risk for AD. Retromers are a family 
of proteins that mediate the retrieval of transmembrane pro-
teins from the endosomes to the trans-Golgi network. Mis-
regulation of retromers or retromer-associated proteins in-
fluences endosomal localization of APP/BACE1. Here we re-
view the role of retromers in the amyloidogenic processing 
of APP and their pathogenic role in AD. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD), the most common form of 
dementia, is a genetically complex neurological disorder 
with excessive neurodegeneration resulting in the pro-
gressive loss of memory function and cognitive abilities 
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transmembrane proteins to the Golgi. Loss of retromer 
function has been correlated with risk for AD and elevat-
ed levels of A  peptide. In this review, we outline the ba-
sic aspects of retromer structure and function and its in-
volvement in AD.
 Cell Biology of Amyloid Production 
 The amyloidogenic peptide, A  , that is causally linked 
to AD, is liberated from the APP via proteolytic process-
ing by   - and   -secretases. A transmembrane aspartyl 
protease, also termed BACE1, confers   -secretase activity 
by cleaving APP to generate A   [3] .   -Secretase is a mul-
ticomponent complex that is composed of presenilin-1/
presenilin-2, Aph-1 (in humans, Aph-1a or Aph-1b), nica-
strin, and Pen-2  [6, 7] . APP and   -secretase are synthe-
sized in the endoplasmic reticulum, glycosylated to ma-
ture proteins and then transported to the plasma mem-
brane from where they are endocytosed into endosomes.
  -Secretase cleavage of APP occurs predominantly in 
endosomes  [4, 8–12] . The pH of endosomes (pH 4.5–6.0) 
is optimal for   -secretase activity, which explains the re-
quirement for endocytosis. On the other hand,   -secre-
tase cleavage of APP, which precludes the production of 
the toxic A  peptide, occurs at the plasma membrane 
 [13] .   -Secretase components are also synthesized in the 
endoplasmic reticulum but the assembly of the mature 
and functional complex requires the coordinated regula-
tion of the endoplasmic reticulum-Golgi recycling circuit 
 [14, 15] and APP cleavage by   -secretase, to generate A  , 
occurs in post-Golgi compartments, i.e. in endosomes 
 [16] .
 A  that is produced in endosomes can be sorted to 
retrograde compartments such as multivesicular bodies 
via vesicular trafficking. Release of A  from the intracel-
lular compartments is shown to occur via the fusion of 
multivesicular bodies with the plasma membrane  [10, 17] . 
This fusion releases the intraluminal vesicles of multive-
sicular bodies as exosomes, and we have shown that a 
fraction of A  is released in association with exosomes 
 [10] . Although the pathway by which the majority of A  
is released is still unknown, various pieces of evidence 
suggest that the multivesicular body fusion pathway 
could also release the bulk of A  which could contribute 
to the formation of amyloid plaques  [18–20] .
 Since A  production occurs in endosomes, mecha-
nisms that regulate the trafficking of the substrate APP 
and its secretases (  -,   and   -secretases) critically deter-
mine the levels of A  produced. Several observations 
support the involvement of endocytosis in   -amyloid 
generation  [9, 21–25] . For example inhibition of dynamin, 
a GTPase that pinches off endocytic vesicles during inter-
nalization, dramatically reduces   -cleavage of APP and 
also A  production  [10, 11, 26] . Mutating the cytosolic 
sorting signals of APP or BACE1, targeting a BACE1 in-
hibitor to endosomes  [27] or overexpression of rab4, a 
small GTPase that mediates the immediate recycling of 
cargo from early endosomes  [10] , all decreased the gen-
eration of A  . These results conclusively showed that the 
amyloidogenic processing of APP occurs in endosomes. 
Hence retrieval or removal of APP or BACE1 from endo-
somal compartments should lead to a decreased produc-
tion of A  . Many papers suggest that retromers and ret-
romer-associated proteins could regulate A  production 
 [28–34] . In accordance with these observations, muta-
tions/polymorphisms leading to retromer dysfunction 
have been suggested to be a risk factor of AD.
 Retromers 
 First identified in yeast  [35] , retromers were reported 
as membrane coat complex proteins that mediate the re-
trieval of the acid hydrolase receptors from endosomes 
(vacuole in yeast) to the Golgi apparatus. Acid hydrolases 
are sorted to endosomes with the help of the sorting re-
ceptors such as the yeast vacuolar protein sorting 10 
(VPS10) or mammalian mannose-6-phosphate recep-
tors. Once the cargo (in this case, acid hydolases) is deliv-
ered to endosomes, the receptors have to be shuttled back 
to the Golgi in order to initiate a new round of transport 
to endosomes. This retrieval from the endosomes back to 
the TGN is carried out by retromers. Retromers are het-
eropentameric protein complexes composed of mainly 
two components: a structural part made of a dimer of 
sorting nexins (SNX), and he cargo recognition complex 
composed of a vacuolar protein sorting trimer  [36–38] .
 Sorting Nexins 
 The sorting nexins contain a phox homology (PX) do-
main that mediates the binding to phosphoinositides in 
the endosomal membrane. In that way they are able to 
recruit the interacting VPS retromer subunits to endo-
somes. In mammals, the SNX dimer is mainly formed by 
either SNX1/SNX2 and SNX5/SNX6. In addition to the 
PX domain, SNX1 and 2 also contain a BAR (Bin, Am-
phiphysin and Rvs) domain that senses curvature in 
membranes and aids in membrane tubulation, a process 
critically important for the transport of proteins from en-
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dosomes  [39, 40] . A recent study showed that SNX3, not 
the canonical SNX1–2 or 5–6, mediates the retrograde 
sorting of Wnt receptor, Wntless. This study showed that 
SNX3 constitutes an alternative retromer pathway and is 
involved in the secretion of Wnt  [41] .
 Cargo Recognition Complex 
 In retromers, the binding to the cargo (the transmem-
brane protein that needs to be retrieved) is mediated by 
the VPS26-VPS29-VPS35 complex. VPS35 builds the 
core element of the retromer complex and binds to VPS26 
(two isoforms VPS26A and VPS26B), VPS29 and SNX 
proteins  [37, 42] . The role of the two isoforms of VPS26 is 
not yet clear. Structural studies show that both VPS29 
and VPS26 can bind independently to VPS35. Since SNX 
can sense/induce curvature, retromers have been pro-
posed to serve as ‘coats’ for tubulovesicular carriers. Con-
sistent with this assumption, retromer proteins have been 
shown to colocalize with markers of early endosomes, 
late endosomes and some tubular endocytic vesicles that 
carry the cargo to the TGN  [35–38] . Cells deficient in 
VPS26 (either derived from knockout mice or RNAi si-
lenced) fail to retrieve the acid hydrolase receptor pro - 
tein (cation-in dependent mannose-6-phosphate recep-
tor) from endosomes thereby leading to either recycling 
the protein to the plasma membrane or sorting it for 
l ysosomal degradation  [43] . Hence retromers could be 
viewed as part of a sorting machinery that reroutes trans-
membrane proteins from lysosomal degradation to recy-
cling via TGN.
 Retromers in APP Processing and AD 
 APP Trafficking by Retromers 
 In 2005, three independent landmark studies from the 
labs of Scott Small, Jordan Tang and Thomas Willnow 
showed a possible involvement of retromers in AD  [28, 
32, 33] .
 Using model-guided microarray technique to study 
the spatiotemporal control of AD-related genes, Small et 
al.  [33] first discovered that the retromer component, 
VPS35 mRNA levels were misregulated in the brain re-
gion most vulnerable in AD. In addition, protein levels of 
VPS26 were also slightly reduced in the entorhinal cortex 
of AD patient samples. While the protein levels of VPS35 
were low in AD patients, the mRNA levels were consider-
ably higher. This inverse relationship of high mRNA and 
low protein could be attributed to many reasons includ-
ing accelerated degradation of the VPS35 protein and 
slower turnover of its mRNA. Experimentally induced 
reduction of VPS35 using siRNA in HeLa cells increased 
A  40 levels by 37% and overexpression of VPS35 de-
creased A  40 levels by 40%. These results suggest that 
retrieval of APP from endosomes to TGN regulates A  
production  [4, 5] . Recently, it was shown that this retriev-
al is dependent on APP phosphorylation at its serine 655 
residue  [44] . In an attempt to establish a functional link 
between the retromer complex and A  -dependent be-
havioral deficits observed in late-onset AD (LOAD), 
Small and his group also characterized two genetically 
modified animal models addressing the role of retromers 
in AD  [34] . They observed altered hippocampal-depen-
dent memory function and long-term potentiation in the 
retromer-deficient mice and an increase in neuronal loss 
in retromer-deficient flies which expressed human APP 
and BACE1. This neuronal loss was accompanied by ac-
cumulation of human A  peptides, suggesting a func-
tional correlation between retromers and A  -induced 
neurodegeneration.
 A few years ago, Thomas Willnow and his group iden-
tified a sorting protein-related receptor containing low-
density lipoprotein receptor class A repeats (SorLA), a 
transmembrane protein that is expressed in neurons to 
be involved in the intracellular transport and process - 
ing of APP to A   [28] . Sorting protein-related recep - 
tor (SorLA, encoded by the SORL1 gene) is a type 1 
 membrane protein with structural similarity to VPS10. 
Through this sequence, SorLA binds to the retromer 
complex and serves as an adaptor protein  [29, 31] and 
serves as an adaptor protein for interacting proteins such 
as APP. Retromers can bind to APP in endosomal com-
partments and transport it retrogradely to the TGN. It 
has been shown that SorLA levels are reduced in affected 
brain areas of AD patients  [28] . Furthermore, perturba-
tions within this retrograde transport are shown to be 
associated with increased production of A  , neurodegen-
eration and finally LOAD  [28] . But the exact mechanism 
of retromer function in APP trafficking and A  secretion 
is still unknown. Willnow and colleagues found that 
 SorLA interacted with APP and that both proteins colo-
calized in endosomal and Golgi compartments. More-
over, overexpression of SorLA redistributed APP to Golgi 
thereby reducing the residency time of APP and BACE in 
the early endosomes ( fig. 1 ). Consequently, A  levels were 
decreased in SorLA overexpression conditions while 
 SorLA ablation in knockout mice increased A  levels. In-
terestingly, frontal cortex samples from AD patients 
showed decreased SorLA expression compared to healthy 
controls.
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 The relevance of these findings to AD was reinforced 
when Peter St. George-Hyslop’s group  [30] identified 
inherited variants of SORL1 that were associated with 
LOAD. Since retromer proteins have been shown to reg-
ulate A  generation in endosomes and because they 
were misregulated in AD, Rogaeva et al.  [30] investi-
gated the genetic association between AD and single-
nucleotide polymorphisms in VPS10P-containing pro-
teins, sortilin and sortilin-related receptors. They found 
6 single-nucleotide polymorphisms in SORL1 that are 
significantly associated with AD. Out of these six sin-
gle-nucleotide polymorphisms, three of them have been 
shown to decrease SORL1 expression by approximately 
50% in haplotype carriers. TIn this study, it was also 
shown endogenous SORL1 directly interacted with the 
endogenous APP holoprotein and with VPS35 but does 
not interact with BACE1. While overexpression of 
SORL1 decreased A  production, RNAi-mediated si-
lencing of SORL1 increased sAPP  (149%) and A  pro-
duction (202%) in this study. Interestingly, VPS26A 
knockdown significantly increased A  40 (186%) and 
A  42 (183%). Similar results were obtained in fly and 
mouse models of AD. These studies clearly demonstrat-
ed that SORL1 plays a key physiological role in the dif-
ferential sorting of APP holoprotein and that retromer 
deficiency contributes to the pathogenesis of AD.
 Several other studies have substantiated the retromer 
findings. Recently another retromer-associated protein, 
SorCS1, was also found to be involved in APP metabolism 
 [45] . Here again, overexpression of SorCS1 reduced A  
generation. SorCS1, also implicated in type 1 and 2 diabe-
tes mellitus, interacts with APP, SORL1 and VPS35. Keep-
ing in line with these observations, SorCS1 hypomorphic 
mice exhibited a profound decrease in VPS35 levels (49%). 
SorCS1 hypomorphic mice had increased levels of   /  -
CTF, A  40 and A  42. Interestingly, these differences 
were found when hypomorphic female mice were com-
pared to wild-type female mice, but not when males and 
females were compared as a group. Interestingly, SorCS1 
is a VPS10 family member and all these results suggest 
that SorCS1 might have the same role as SORL1 in APP 
metabolism. One other study also showed that SorCS1 
negatively regulated A  production and found that inher-
ited variants in SorCS1 were associated with AD  [46] .
 While all these studies showed that retromers nega-
tively regulate amyloidogenic APP processing one recent 
study, however, found that retromer disruption decreased 
A  40 secretion such that the A  42/A  40 ratio was 
changed  [47] . They found that RNAi-mediated silencing 
of VPS35, the core component of the retromer complex, 
changed neither the amount nor the cellular distribution 
of total cellular APP. They also found no effect on the en-
docytosis of cell surface APP. However, VPS35 knock-
down increased the ratio of secreted A  42/A  40 mostly 
due to a decrease in A  40 secretion. The authors found 
that retromer disruption upon VPS35 knockdown sig-
nificantly increased secretion of APP C-terminal frag-
ments in exosomal vesicles thereby reducing the amount 
of A  production. How do these results fit with the previ-
ous observations that retromer disruption indeed in-
creases   -cleavage of APP and A  production? While 
this study concentrated on VPS35, it could still be possi-
ble that other components have retromer-complex-inde-
pendent functions.
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 Fig. 1. Retromer-mediated sorting at the endosomes. APP, BACE1 
and   -secretase complex are trafficked to the cell surface and in-
ternalized into early endosomes. In the early endosomes, the pH 
is conducive for   -secretase cleavage of APP. APP retrieval from 
the early endosomes could occur via a rab4-mediated sorting di-
rectly to the plasma membrane. Alternatively, retromer proteins 
bind to retrieval receptors such as SorLA/SorCS1 which in turn 
bind to APP and mediate their transport to the TGN. In the 
 absence of functional retromers or retrieval receptors, APP (or 
BACE1 in the case of GGA3) localization in endocytic compart-
ments is enhanced leading to enhanced production of A  . 
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 Retromer-Dependent Trafficking of BACE1 
 Not only APP but also BACE1 has been shown to be 
dependent on retromer-mediated trafficking. As early as 
2005, Jordan Tang’s group  [32] showed that BACE1 traf-
ficking from endosomes to TGN is dependent on a pro-
tein called GGA (Golgi-localized   -ear-containing ARF-
binding protein) which facilitates the recycling of BACE1 
( fig. 1 ). This study was also one of the first to show that 
a retromer subunit, VPS26, is directly involved in APP 
processing. In line with this observation, caspase-medi-
ated cleavage of GGA-3 during apoptosis has been shown 
to stabilize BACE1 and enhance A  production  [48] . An-
other retromer-associated protein, sortilin, is shown to 
bind BACE1 and a C-terminal truncated sortilin redis-
tributed BACE1 to endosomes  [49] . This study showed 
that overexpression of sortilin increased   -cleavage of 
APP and A  levels whereas its reduction via RNAi de-
creased the amyloidogenic processing of APP. These 
findings, however, are in sharp contrast with the previ-
ously reported role of retromers in APP processing as 
this study shows a positive role for retromers in A  pro-
duction. The reason for this is unclear but reduced recy-
cling of BACE1 in the absence of functional sortilin lev-
els is attributed for the reduction in A  production. In 
support of this, the amount of sortilin has been shown to 
be elevated in AD patients  [48] . Recently, in a proteomic 
characterization, SNX6 was identified as a BACE1-inter-
acting protein and validation experiments suggest that 
this SNX6-dependent trafficking of BACE1 regulates A  
production  [50] .
 Conclusion and Outlook 
 The findings on retromers and APP processing fur-
ther underscore the importance of membrane trafficking 
in AD  [51, 52] . However, a lot more questions need to be 
addressed. Where do retromers act in the endocytic com-
partment? Since they regulated A  production which 
largely occurs in early endosomes, it is suggested that the 
retromer pathway could act at the level of early endo-
somes. It is not yet clear whether retromer-associated 
proteins act at the level of early or late endosomes or both. 
A recent study on the intracellular transport of Furin and 
TGN38, two proteins that recycle between the TGN and 
plasma membrane, suggests that while TGN38 traffick-
ing is retromer-dependent, trafficking of Furin involved 
rab9, a rab protein involved in late endosome-TGN  [53] . 
Through extension, this study suggests that retromers 
probably act at the level of early endosomes and that car-
goes that are retrieved from the late endosomal compart-
ments are retromer-independent.
 Are   -secretase components retrieved by retromers 
from the endosomes? How do the polymorphisms in 
SORL1 and SorCS1 affect the retrieval of Wntless and 
thereby Wnt signaling  [54] ? Disrupted Wnt signaling is 
observed in AD  [55] . It would be interesting to study if 
there is an underlying common cause through retromers. 
How are APP mutations affected through this trafficking 
pathway? Is Notch trafficking affected through retromers? 
What are the roles of retromers in synaptic function and 
dysfunction? Clearly an exciting period lies ahead to un-
derstand the molecular and cellular basis of LOAD. 
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